Company news
China Sxt Pharmaceuticals, Inc. (NASDAQ:SXTC) news
China Sxt Pharmaceuticals, Inc. news releases on 6ix. Latest, Jul 24, 2026: Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering…
Press releases & updates
Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)
July 24, 2026
China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering
July 23, 2026
China SXT Pharmaceuticals, Inc. Announces Share Re-classification
March 22, 2026
China SXT Pharmaceuticals, Inc. Announces Share Consolidation
January 30, 2026
CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC INITIATIVE TO APPLY AI TECHNOLOGY ACROSS THE TCM SUPPLY CHAIN
January 15, 2026
China SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct Offering
January 9, 2026
CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC AI INSIGHTS INITIATIVE TO OPTIMIZE TRADITIONAL CHINESE MEDICINE PORTFOLIO, ENHANCE MARKET ANALYSIS AND EXPLORE AI-SUPPORTED CLINIC DEPLOYMENT
January 8, 2026
China SXT Pharmaceuticals Has Regained Compliance with Nasdaq’s Minimum Bid Price Deficiency
March 17, 2025
China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency
October 6, 2024
China SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq’s Minimum Bid Price Rule
October 25, 2023
China SXT Pharmaceuticals Announces One-for-Twenty-five Reverse Stock Split
October 3, 2023
China SXT Pharmaceuticals, Inc. Receives 180-day Extension from Nasdaq to Meet Minimum Bid Price Rule
May 9, 2023
China SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share Split
May 17, 2022
China SXT Pharmaceuticals, Inc. Enters into Securities Purchase Agreement to Issue a 6% Convertible Promissory Note in the Original Principal Amount of $2.8 Million
March 13, 2022
China SXT Pharmaceuticals, Inc. Announces Successful Closing of $4.1 Million Follow-on Underwritten Offering of Ordinary Shares and Pre-Funded Warrants With Simultaneous Exercise of the Over-Allotment
January 19, 2022
China SXT Pharmaceuticals, Inc. Prices $3.5 Million Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares
January 17, 2022
China SXT Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares
January 13, 2022
China SXT Pharmaceuticals, Inc. Adds Newly Developed Kuihuapan and Zhudanfen Advanced TCMP Products, and Announces the Expected Continuous Growth of Its Production Capacity of Luxuejin
January 13, 2022
China SXT Pharmaceuticals, Inc. Obtained a New Pharmaceutical Manufacturing Permit and Passed Its GMP Compliance-Inspection
October 17, 2021
China SXT Pharmaceuticals, Inc. Announces 1 for 4 Reverse Share Split
February 18, 2021
China SXT Pharmaceuticals, Inc. Enters into Non-Binding LOI to Acquire Jiangsu Renji Pharmaceutical Chain Co., Ltd.
February 10, 2021
China SXT Pharmaceuticals, Inc. Announces That It Received a Grant Supported by City Government
March 15, 2020
China SXT Pharmaceuticals, Inc. Announces Plans to Increase Production
January 23, 2020
China SXT Pharmaceuticals, Inc. Announced Regulatory Approval of Its DNA Exam Laboratory
January 15, 2020
China SXT Pharmaceuticals, Inc. Granted to Establish Taizhou Research Center for Advanced TCMP Engineering Techniques
September 10, 2019
China SXT Pharmaceuticals, Inc. Announces Filing of Annual Report on Form 20-F for Year Ended March 31, 2019
August 18, 2019
China SXT Pharmaceuticals, Inc. Receives New Pharmaceutical GMP Certificate
August 11, 2019
China SXT Pharmaceuticals, Inc. Announces TCM Homologous Supplements Production
July 2, 2019
China SXT Pharmaceuticals, Inc. Being Admitted to Hi-tech Zone of Huangshan City in Anhui Province
May 21, 2019
China SXT Pharmaceuticals, Inc. Announces Pricing of a $15 Million PIPE Financing
April 16, 2019
China SXT Pharmaceuticals, Inc. Receives National High-tech Enterprise Qualification
April 1, 2019